Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with indenoisoquinolinesXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965Xx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostatXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drugXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsinXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostatXx_NEWLINE_xXPatients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-afliberceptXx_NEWLINE_xXPregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128Xx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocolXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449Xx_NEWLINE_xXBreastfeeding should be discontinued if the mother is treated with sEphB4-HSAXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdRXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxelXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclaxXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomideXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)Xx_NEWLINE_xXPregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970Xx_NEWLINE_xXPregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabineXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agentsXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavirXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treatedXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiationXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdRXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385Xx_NEWLINE_xX